Upstream Bio, Inc. UPB Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -5,176.5%+442pp | -5,618.8%-599pp | -5,020.1%-555pp | -4,464.6%-337pp | -4,127.4%— | |
| Net margin | -4,719%+307pp | -5,026%-659pp | -4,366.8%-530pp | -3,836.6%-388pp | -3,448.7%— | |
| EBITDA margin | -5,170.7%+442pp | -5,612.2%-599pp | -5,013.6%-554pp | -4,459.2%— | —— | |
| Liquidity | ||||||
| Current ratio | 23.1×-3.0× | 26.2×-6.5× | 32.7×-5.6× | 38.3×— | —— | |
| Quick ratio | 23.1×-3.0× | 26.2×-6.5× | 32.7×-5.6× | 38.3×— | —— | |
| Cash ratio | 7.1×-0.5× | 7.6×+1.5× | 6.1×+1.9× | 4.2×— | —— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | —— | —— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | —— | |
| Per Share | ||||||
| Book value per share | $5.60-11.3% | $6.31-10.1% | $7.02-7.7% | $7.60-8.5% | $8.31-75.8% | |
| Valuation | ||||||
| Market capitalization | $346.11M-40.9% | $1.47B+44.7% | $1.01B— | —— | —— | |
| Enterprise value | $250.5M-51.4% | $1.37B+44.9% | $943.29M— | —— | —— | |
| Price / sales | 104.2×-151× | 514.1×+152× | 362.3×— | —— | —— | |
| Price / book | 1.1×-0.2× | 4.3×+1.6× | 2.7×— | —— | —— | |
| EV / sales | 75.4×-149× | 478.9×+142× | 337×— | —— | —— | |
| Earnings yield | -45.3%-31.8pp | -9.8%+2.3pp | -12.1%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Upstream Bio, Inc.'s ratios come from?
- Every ratio is computed from Upstream Bio, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
